Copyright Reports & Markets. All rights reserved.

Global Cancer Hormone Therapy Drugs Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Cancer Hormone Therapy Drugs Market Overview

    • 1.1 Product Overview and Scope of Cancer Hormone Therapy Drugs
    • 1.2 Classification of Cancer Hormone Therapy Drugs by Types
      • 1.2.1 Global Cancer Hormone Therapy Drugs Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Cancer Hormone Therapy Drugs Revenue Market Share by Types in 2018
      • 1.2.3 Tamoxifen
      • 1.2.4 Aromatase Inhibitors
      • 1.2.5 Antiandrogens
      • 1.2.6 Androgen Synthesis Inhibitors
      • 1.2.7 Other
    • 1.3 Global Cancer Hormone Therapy Drugs Market by Application
      • 1.3.1 Global Cancer Hormone Therapy Drugs Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Breast Cancer
      • 1.3.3 Prostate Cancer
    • 1.4 Global Cancer Hormone Therapy Drugs Market by Regions
      • 1.4.1 Global Cancer Hormone Therapy Drugs Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Cancer Hormone Therapy Drugs Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Cancer Hormone Therapy Drugs Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Cancer Hormone Therapy Drugs Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Cancer Hormone Therapy Drugs Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Cancer Hormone Therapy Drugs Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Cancer Hormone Therapy Drugs (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Roche
      • 2.1.1 Business Overview
      • 2.1.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Roche Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Amgen
      • 2.2.1 Business Overview
      • 2.2.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Amgen Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Pfizer
      • 2.3.1 Business Overview
      • 2.3.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Pfizer Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Teva
      • 2.4.1 Business Overview
      • 2.4.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Teva Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Takeda
      • 2.5.1 Business Overview
      • 2.5.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Takeda Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Samyang Biopharmaceuticals
      • 2.6.1 Business Overview
      • 2.6.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Samyang Biopharmaceuticals Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Tolmar
      • 2.7.1 Business Overview
      • 2.7.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Tolmar Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 AstraZeneca
      • 2.8.1 Business Overview
      • 2.8.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 AstraZeneca Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Novartis
      • 2.9.1 Business Overview
      • 2.9.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Novartis Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Aspen
      • 2.10.1 Business Overview
      • 2.10.2 Cancer Hormone Therapy Drugs Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Aspen Cancer Hormone Therapy Drugs Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Cancer Hormone Therapy Drugs Market Competition, by Players

    • 3.1 Global Cancer Hormone Therapy Drugs Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Cancer Hormone Therapy Drugs Players Market Share
      • 3.2.2 Top 10 Cancer Hormone Therapy Drugs Players Market Share
    • 3.3 Market Competition Trend

    4 Global Cancer Hormone Therapy Drugs Market Size by Regions

    • 4.1 Global Cancer Hormone Therapy Drugs Revenue and Market Share by Regions
    • 4.2 North America Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 4.5 South America Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)

    5 North America Cancer Hormone Therapy Drugs Revenue by Countries

    • 5.1 North America Cancer Hormone Therapy Drugs Revenue by Countries (2014-2019)
    • 5.2 USA Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)

    6 Europe Cancer Hormone Therapy Drugs Revenue by Countries

    • 6.1 Europe Cancer Hormone Therapy Drugs Revenue by Countries (2014-2019)
    • 6.2 Germany Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 6.3 UK Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 6.4 France Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Cancer Hormone Therapy Drugs Revenue by Countries

    • 7.1 Asia-Pacific Cancer Hormone Therapy Drugs Revenue by Countries (2014-2019)
    • 7.2 China Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 7.5 India Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)

    8 South America Cancer Hormone Therapy Drugs Revenue by Countries

    • 8.1 South America Cancer Hormone Therapy Drugs Revenue by Countries (2014-2019)
    • 8.2 Brazil Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Cancer Hormone Therapy Drugs by Countries

    • 9.1 Middle East and Africa Cancer Hormone Therapy Drugs Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Cancer Hormone Therapy Drugs Revenue and Growth Rate (2014-2019)

    10 Global Cancer Hormone Therapy Drugs Market Segment by Type

    • 10.1 Global Cancer Hormone Therapy Drugs Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Cancer Hormone Therapy Drugs Market Forecast by Type (2019-2024)
    • 10.3 Tamoxifen Revenue Growth Rate (2014-2024)
    • 10.4 Aromatase Inhibitors Revenue Growth Rate (2014-2024)
    • 10.5 Antiandrogens Revenue Growth Rate (2014-2024)
    • 10.6 Androgen Synthesis Inhibitors Revenue Growth Rate (2014-2024)
    • 10.7 Other Revenue Growth Rate (2014-2024)

    11 Global Cancer Hormone Therapy Drugs Market Segment by Application

    • 11.1 Global Cancer Hormone Therapy Drugs Revenue Market Share by Application (2014-2019)
    • 11.2 Cancer Hormone Therapy Drugs Market Forecast by Application (2019-2024)
    • 11.3 Breast Cancer Revenue Growth (2014-2019)
    • 11.4 Prostate Cancer Revenue Growth (2014-2019)

    12 Global Cancer Hormone Therapy Drugs Market Size Forecast (2019-2024)

    • 12.1 Global Cancer Hormone Therapy Drugs Market Size Forecast (2019-2024)
    • 12.2 Global Cancer Hormone Therapy Drugs Market Forecast by Regions (2019-2024)
    • 12.3 North America Cancer Hormone Therapy Drugs Revenue Market Forecast (2019-2024)
    • 12.4 Europe Cancer Hormone Therapy Drugs Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Cancer Hormone Therapy Drugs Revenue Market Forecast (2019-2024)
    • 12.6 South America Cancer Hormone Therapy Drugs Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Cancer Hormone Therapy Drugs Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Hormone Therapy, (also called hormonal therapy, hormone treatment, or endocrine therapy) is a cancer treatment that blocks or lowers the growth of cancer that uses hormones to grow. Doctors use it to treat some cancers such as breast and prostate cancer.

      Scope of the Report:
      The global Cancer Hormone Therapy Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Hormone Therapy Drugs.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Cancer Hormone Therapy Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Hormone Therapy Drugs market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Roche
      Amgen
      Pfizer
      Teva
      Takeda
      Samyang Biopharmaceuticals
      Tolmar
      AstraZeneca
      Novartis
      Aspen

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Tamoxifen
      Aromatase Inhibitors
      Antiandrogens
      Androgen Synthesis Inhibitors
      Other

      Market Segment by Applications, can be divided into
      Breast Cancer
      Prostate Cancer

      Buy now